Vertex Pharmaceuticals Incorporated
- Vertex Pharmaceuticals Inc. dropped 0.4% to $467.98 after the biotech company posted lower income in the fourth quarter ending in December.
Revenue increased to $2.91 billion from $2.52 billion, net income dropped to $913.0 million from $968.8 million, and earnings per diluted share fell to $3.50 from $3.71 a year ago.
Revenue growth was primarily driven by the continued performance of TRIKAFTA/KAFTRIO, a prescription medicine used for cystic fibrosis treatment.
For fiscal 2025, the company estimated revenue between $11.75 billion and $12.0 billion, compared to $11.02 billion in 2024.
Feb 11, 2025
If you want to see the full data, please log in to your account. Logging in gives you complete access to all available information, features, and detailed insights that are not visible to guest users.